Abstract
Objective: To detect maternal serum PAPP-A levels at 11-13 weeks 6 day of gestation in pregnancies who subsequently develop pre-eclampsia and to evaluating the role of these screening PAPP-A in the prediction of pre-eclampsia. Materials and methods: Prospective screening study for preeclampsia in pregnant attending their first hospital visit at 11-13 weeks 6 of gestation. The performance of screening for PE by serum PAPP-A and free βhCG were determined. Results: Of 2,998 patients with complete outcome data, there were 3.74% of hypertension disorder, and 2.84% cases of pre-eclampsia. free βhCG levels were no different significantly in pregnancy who developed pre-eclampsia compared to the control group. PAPP-A levels were significantly lower in pregnants who developed early pre-eclampsia (0.653 MoM) and late pre-eclampsia (0.744 MoM) compared to the control group (1.039 MoM).In screening for PE by combinematernal factors and PAPP-A,at false positive rate of 5%, the estimateddetection rates were 36.4% and the detection rates were 54.6%, at at false positive rate of 10%. Conclusion: Low PAPP-A levels are associated with the development of preeclampsia; however, it should be combined with other tests to increase effectiveness of hypertension disorder screening at the first trimester. Key words: preeclampsia; gestational hypertension; screening; PAPP-A.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call